GlassScriptPhysician profile
Richard Wilroy
NPI 1760672836
$730.01
in general payments reported to CMS, 2019-2025
14 companies · $35.17 in 2025
The $35.17 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $362 · 2021: $74.23 · 2022: $71.41 · 2023: $13.12 · 2024: $37.88 · 2025: $35.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $337.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $69.39 | 2019-2022 | |
| Amgen INC. | $66.15 | 2021-2025 | Evenity, Prolia, Otezla |
| Allergan, INC. | $43.39 | 2019 | |
| Abbvie INC. | $42.41 | 2021-2022 | |
| Mylan Specialty L.P. | $32.06 | 2021-2022 | |
| Lilly USA, LLC | $30.05 | 2020-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $19.97 | 2021 | |
| Livanova USA, INC. | $18.80 | 2019 | |
| Merck Sharp & Dohme LLC | $16.37 | 2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $15.44 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.78 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wilroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.